The Zacks Analyst Blog Highlights: Medtronic, Covidien, Abbott Laboratories, Mylan and Burger King Worldwide
PR Newswire - Thu Sep 25, 9:04AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Medtronic, Inc. (NYSE:MDT-Free Report), Covidien plc (NYSE:COV-Free Report), Abbott Laboratories (NYSE:ABT-Free Report), Mylan, Inc. (Nasdaq:MYL-Free Report) and Burger King Worldwide, Inc. (NYSE:BKW-Free Report).
Ex-CEO charged in ballplayer's insider trade
AP - Wed Sep 24, 10:03PM CDT
SANTA ANA, Calif. (AP) — Federal prosecutors say the former CEO of a Southern California medical device company has been indicted on allegations that he shared insider trading secrets with former Baltimore Orioles All-Star Doug DeCinces.
Will New Treasury Rules Contain Tax Inversions? - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Sep 24, 9:22AM CDT
Late on Monday, the U.S. Treasury Department outlined new rules to deter domestic companies from moving abroad in an attempt to reduce tax payments.
Expiration of the U.S. Tender Offer for CFR Pharmaceuticals S.A.
PR Newswire - Wed Sep 24, 8:00AM CDT
Abbott today announced the expiration of the tender offer for the purchase from U.S. holders of the ordinary shares of CFR Pharmaceuticals S.A., a Chilean corporation, and for the purchase from all holders, wherever resident, of CFR's outstanding American Depositary Shares. The offer was not conditioned on the receipt of any minimum number of ordinary shares or American Depositary Shares being tendered.
Medical Diagnostic Devices Research Digest - H1 2014: Latest News for Medical Devices, In-Vitro Diagnostic Devices & Medical Imaging Devices
M2 - Wed Sep 24, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rnbznw/medical) has announced the addition of the "Medical Diagnostic Devices Research Digest - H1 2014" subscription to their offering. The Medical Diagnostic Devices Research Digest is a round-up of all the most important research in the industry each quarter available as an annual subscription, gathered from over 50 sources including associations, market intelligence companies, Journals, company news articles , consultants and industry participants. Updated quarterly, the Digest allows you to: - Quickly update yourself on the latest research findings, gathered and organised for you. - Get our Expert Analysts' perspectives on the latest research. - Link through to the original research to review or purchase. Key Topics Covered: 1 Global Medical Devices Research - Medical Devices M&A Value Falls by Over Half in 2013 Against 2012 - Global Medical Devices Market Showing Only Moderate Growth - Big Fall In Regulatory Approvals of Medical Devices - Top 10 Medical Device Companies 2013 - Cyber-Attacks on Medical Devices Endanger Patients' Lives - US Medical Device Manufacturers Paid $1bn in Excise Tax In 2013 - Strategic Rationale of Medtronic-Covidien Deal - Manufacturing Costs Of Medical Devices Significantly Lower Outside The U.S. - New Trends in Private Healthcare Service Providers in APAC, But Hospitals Remain the Major Providers - China's Healthcare Reform Continues to Drive Its Medical Devices Market 2 In Vitro Diagnostic Devices Research - Global In Vitro Diagnostic (IVD) Devices Market Moderate Growth - Johnson & Johnson Divests Its IVD Business - Becton Dickinson Leads Global Flow Cytometry Market - Clinical Chemistry And Coagulation Tests Dominate North America IVD Market - Cost Of Cholesterol Tests Vary Widely Across The U.S. - Molecular Diagnostics' Rapid Growth In The U.S. IVD Market - U.S. Companion Diagnostics Significant Growth - Hospital-Acquired Infections (HAI) Drive The U.S. Infectious Diseases Testing Market - U.S. IVD Market, Competitive Landscape 2013 - New Entrants Gain Share In The U.S. Blood Testing Market - European Companion Diagnostics' Remarkable Growth - European Law Restricts German IVD Market Growth - French IVD Market Restraints - French Government Strengthens Transparency In Healthcare Sector - Public Healthcare Budget Impacts On Italian IVD Market - Spanish IVD Market Declines Substantially - Nail Test For Bone Quality Launched In The UK - Taxes In Brazil Suppress IVD Market Growth - Brazilian IVD Manufacturers Gain Momentum - Rapid Growth Forecast For Chinese Digital Pathology Market - Public-Private Partnerships Drives Indian IVD Market - Indian IVD Market - Competitive Landscape - Indian Clinical Laboratories Still Use Manual Methods 3 Medical Imaging Devices Research - Diagnostic Ultrasound Market In Developed Economies Depends On Replacement Of Already Installed Systems - Film-Screen Mammography (FSM) Systems Usage Phased Out In Europe - Adoption Of Breast Tomosynthesis System Faster In Europe Than The U.S. - Prices Of CT And MRI Scan Vary Widely Across The U.S. - Medical Imaging Contribution To Washington State's Economy - Mammography Reduces U.S. Mortality Rate - Canadian Initiative Controls Overutilization Of Lumbar MRI Scans - China's Diagnostic X-Ray Imaging Market Sees Rapid Growth Companies Mentioned - Abbott - Abbott Laboratories - Agappe Diagnostics - Arkray - Beckman Coulter Inc. and Becton Dickinson - Bio-Rad and Danaher - CPC Diagnostics - Crescent Diagnostics - DASA Diagnostic Laboratory Group - EMD Millipore - GrupoFleury and Hermes Pardini - Hologic - Hologic - iCyt Sysmex - Johnson and Johnson - LabCorp - Lilac Medicare - Merck - Mindray - Ortho-Clinical Diagnostics - Partec - Qiagen - Quest Diagnostics - Roche Diagnostics - Siemens Healthcare - Sony Technology - Theranosis - Thermo fisher and Alere - Transasia Bio-Medicals - Tulip and Bhat-Biotech For more information visit http://www.researchandmarkets.com/research/rnbznw/medical
New Developments in the Companion Diagnostics Market 2014
M2 - Wed Sep 24, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zlp33x/companion) has announced the addition of the "Companion Diagnostics Market" report to their offering. There had been a slow market uptake of companion diagnostics because companion tests lacked FDA approval, which prevented pharmaceutical companies from promoting the diagnostic. But the realization that companion diagnostics can decrease costs by identifying the patient population that will most likely benefit from a therapy and ruling out those therapies not likely to be effective has made companion diagnostics important to the delivery of care. This report, Companion Diagnostics Markets tracks these new developments and focuses on companion diagnostics in medicine in 2013 and 2014. The report provides product analysis for the five broad areas of medical companion diagnostics and market information: Cancer Cardiovascular and Blood Metabolic Infection Neurological Market Size by Disease Area, 2013 and 2018Companion diagnostics have met with considerable challenges in penetrating the market, but are now rising to the forefront of pharmaceutical development and treatment, increasing the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes. Companion diagnostics and biomarkers provide insight into understanding disease processes and ways that medicines can work to counteract the disease. The majority of competitive participation for companion diagnostics is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. There are numerous companies in the market which include large multiproduct companies such as Roche and Abbott and small niche developers such as 20/20 GeneSystems. Key Topics Covered: ONE: EXECUTIVE SUMMARY TWO: INTRODUCTION TO THE COMPANION DIAGNOSTICS INDUSTRY THREE: INDUSTRY TRENDS FOUR: COMPANION DIAGNOSTIC PRODUCTS FIVE: MARKET SIZE AND GROWTH SIX: COMPANY PROFILES - 20/20 Genesystems, Inc. - Abbott Laboratories - Affymetrix - Asuragen, Inc. - Beckman Coulter, Inc - Becton, Dickinson - Biocartis S.A. - Biodesix, Inc. - Biomerieux Sa - Bioreference Laboratories, Inc - Biotheranostics, Inc. - Cardiodx, Inc - Celera Alameda - Clarient, Inc - Decode Genetics, Inc. - Diagenic Asa - Genomic Health, Inc. - Genoptix Medical Laboratory - Illumina, Inc. - Johnson & Johnson - Life Technologies Corporation (Part Of Thermo Fisher) - Myriad Genetics, Inc. - Nanostring Technologies, Inc. - Opko Health, Inc. - Provista Dx - Qiagen N.V. - Roche - Siemens Healthcare - Singulex, Inc - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/zlp33x/companion
After Yesterday's Decline of 2.09%, Abbott Laboratories Offers Investors Better Value
Comtex SmarTrend(R) - Tue Sep 23, 3:53PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $42.49 to a high of $43.16. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $43.22 on volume of 6.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Abbott Laboratories Shares Up 10.8% Since SmarTrend's Buy Recommendation (ABT)
Comtex SmarTrend(R) - Tue Sep 23, 9:46AM CDT
SmarTrend identified an Uptrend for Abbott Laboratories (NYSE:ABT) on April 22nd, 2014 at $38.75. In approximately 5 months, Abbott Laboratories has returned 10.83% as of today's recent price of $42.94.
Research and Markets: China POCT Market 2014-2018: Abbott Laboratories, Bayer HealthCare, F. Hoffmann-La Roche & LifeScan Dominates the Market
Business Wire - Tue Sep 23, 3:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r3shd9/poct_market_in) has announced the addition of the "POCT Market in China 2014-2018" report to their offering.
China POCT Market 2014-2018: Abbott Laboratories, Bayer HealthCare, F. Hoffmann-La Roche & LifeScan Dominates the Market
M2 - Tue Sep 23, 3:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gch85q/poct_market_in) has announced the addition of the "POCT Market in China 2014-2018" report to their offering. The POCT market in China to grow at a CAGR of 20.69% over the period 2013-2018 POCT, also called near-patient testing, is performed outside a clinical laboratory. It helps in making fast clinical decisions, and hence in administrating appropriate treatments and medication. POCT is gaining popularity due to the increasing incidence and prevalence of lifestyle diseases such as diabetes, heart disease, and obesity. It is generally cost-effective and user-friendly. POCT devices are standardized to minimize errors during the diagnosis of patients. POCT plays a major role in improving patients' quality of life. The expanding economy of China is one of the major trends witnessed in this market. The Government of China is making efforts to improve healthcare infrastructures, which has benefited the POCT market. According to the report, one of the major drivers in the market is the increase in innovations in technology to provide efficient and inexpensive devices to diagnose and treat diseases. Advances in technology and innovations in the Healthcare industry have resulted in the development of equipment with technology that is customized as per the needs of the patient. Further, the report states that one of the major challenges in the market is the advances in technology. The entry of new technology in the market forces the frequent elimination of the POCT products of the large vendors. To calculate the market size, the report considers the revenue generated through the following applications of POCT: - Blood glucose testing - Cholesterol testing - Infectious disease testing - Blood gas testing - Cardiac biomarkers testing - Pregnancy testing - Others (such as cancer biomarker, electrolyte analyzers, blood coagulation testing, tumor marker, and urinalysis testing) Key Vendors - Abbott Laboratories - Bayer HealthCare - F. Hoffmann-La Roche - LifeScan Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Market Segmentation by Technology - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape For more information visit http://www.researchandmarkets.com/research/gc..._market_in
Novo Nordisk Reveals Fresh Data on Xultophy for Diabetes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 5:20PM CDT
Novo Nordisk (NVO) announced data from new analyses of the phase IIIa DUAL I and DUAL II studies on Xultophy.
Novartis' (NVS) Data on Anti-Cancer Drug LBH589 Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 3:45PM CDT
Novartis (NVS) announced that positive data on its pipeline candidate, LBH589 (panobinostat), was published in The Lancet Oncology.
Research and Markets: Global PCR Technologies Global Market 2014-2020
Business Wire - Mon Sep 22, 3:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rb5tts/pcr_technologies) has announced the addition of the "PCR Technologies Global market - Forecast to 2020" report to their offering.
Global PCR Technologies Global Market 2014-2020
M2 - Mon Sep 22, 3:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kvrrv/pcr_technologies) has announced the addition of the "PCR Technologies Global market - Forecast to 2020" report to their offering. Some of the key players in the PCR market are Abbott Laboratories, Affymetrix, inc., Takara bio, Agilent Technologies, Beckman Coulter Inc., Quanta biosciences, Bio-Rad, Becton, Dickinson and Co., GE Healthcare, Sigma-Aldrich Corp., and Roche. Polymerase chain reaction (PCR) is a gene amplification technique that amplifies a single or a few copies of a piece of DNA across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence. PCR plays a crucial role in understanding the genetic diseases and is also used in the characterization and detection of infectious disease organisms in diseases like Lyme disease, AIDS, middle ear infection and tuberculosis. PCR is an indispensable technique in Biotechnology, drug discovery and clinical diagnostics and it's key applications include DNA sequencing, Forensic science, Genotyping, Bioinformatics, gene expression, genetic mapping and DNA cloning. PCR products market includes Reagents, consumables, instruments, software and services. Some of the key techniques available in market are Standard/basic PCR, Real-time/Q-PCR, Digital PCR (dPCR), Reverse transcriptase PCR, Assembly PCR, Inverse PCR, Nested PCR, Multiplex PCR, Hot start PCR and touchdown PCR Among the various techniques, Q-PCR appears to be the fastest growing in PCR market followed by Reverse-Transcription PCR (RT-PCR) and Assembly. Based on the classification by products/tools, PCR Reagents is expected to be fastest growing PCR market followed by PCR Consumables and Machines. The global PCR market is projected to grow at a healthy rate. North America would account for the largest market share followed by Europe and Asia-pacific. Increasing number of patients suffering from Infectious diseases, Cancers and positive investments in gene therapy and human genome project are further driving the growth of the PCR market. Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 PCR Market by Types 5 PCR Market by Application 6 PCR Market by Technology 7 Regional Market Analysis 8 Company Developments 9 Major Company Profiles - Abbott Laboratories - Becton, Dickinson And Co. - Bio-Rad - Ge Healthcare - Kapa Biosystems - Maxim Biotech - Promega Corp. - Quanta Biosciences Inc. - Roche - Sigma-Aldrich Corp. - Takara Bio - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/4k...chnologies
Global In-Vitro Diagnostics (POC/Rapid Diagnostics) Market 2014-2020
M2 - Mon Sep 22, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kjf5z9/in_vitro) has announced the addition of the "In Vitro Diagnostics (POC/Rapid diagnostics) Global market - Forecast to 2020" report to their offering. The focus of this research report description was on various levels of analysis, industry, market shares, value chain, PESTEL analysis and company profiles which together comprise and augment about competitive landscape, emerging and high growth segments of in vitro diagnostic (molecular diagnostics & point of care testing), emerging technologies. In vitro diagnostics are tests that diagnose and prevent diseases, conditions or infections. IVD tests are performed outside body in an artificial environment on samples such as blood, urine, tissue isolated from human body. IVD is classified into 3 types namely: clinical laboratory testing, near-patient testing, self-testing. IVD market is segmented by-techniques (including immunoassays, point of care, molecular diagnostics, hematology, coagulation, microbiology, clinical techniques, microbiology), product-type (including instruments, reagents, services, data management systems), usability (including disposable, reusable), applications (including diabetes, oncology, cardiology, HIV/AIDS, autoimmune disease, nephrology, drug testing), -end-user (including hospitals, laboratories, academics) and geography (globally). Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Global Ivd Market, By Technique 5. Global Ivd Market, By Products 6. Global Ivd Market, By Application 7. Global Ivd Market, By End-Users 8. Regional Market Analysis 9. Company Developments 10. Major Player Profiles - Abbott Laboratories, Inc. - Becton, Dickinson and company - Biomerieux - Bio-Rad Laboratories, Inc - Danaher Corporation - Johnson and Johnson - Roche Diagnostics - Siemens Healthcare - Sysmex Corporation - Thermo Fischer Scientific, Inc For more information visit http://www.researchandmarkets.com/research/kjf5z9/in_vitro
Dividend Aristocrats: Time to Buy AbbVie Inc Stock?
George Budwell, The Motley Fool - Motley Fool - Fri Sep 19, 11:32AM CDT
Dividend stocks are a powerful force within a well-balanced portfolio because they can dramatically increase the rate of compounding interest through dividend reinvestment plans. Not all dividend stocks are great investment vehicles, however. For...
Jim Cramer's 'Mad Money' Recap: Hooray for the Federal Reserve
at The Street - Wed Sep 17, 7:08PM CDT
Now that the Fed has done the right thing on monetary policy, investors should stop worrying and start thinking about how to make more money, Cramer says.
Look for Shares of Abbott Laboratories to Potentially Pullback after Yesterday's 1.12% Rise
Comtex SmarTrend(R) - Wed Sep 17, 4:27PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $42.76 to a high of $43.57. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $42.97 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Abbott Labs (ABT) to Initiate New Trial on Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 4:05PM CDT
Abbott Labs (ABT) recently announced that it will initiate a trial, ABSORB IV, on bioresorbable vascular scaffold (BVS) Absorb.
Global Hemoglobin A1c Testing Devices (Laboratory Testing Devices & POC testing Devices) Market Analysis 2013-2019
M2 - Wed Sep 17, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjh9n8/hemoglobin_a1c) has announced the addition of the "Hemoglobin A1c Testing Devices Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. 'Testing the levels of glycated hemoglobin provides an assurance to the healthcare practitioner about the patient's blood glucose level. This test can be used for diagnosis and monitoring of hemoglobin A1c levels in diabetic patients. Since A1C test reflects the average amount of glucose for the past 2 to 3 months, it is opined to be more reliable than conventional blood glucose test. Physicians are increasingly prescribing HbA1c test to their patients which will lead to an increase in the test volume. Moreover, rising diabetes incidence rate is a major driver for the HbA1c testing market. With growing awareness about prevention and management of diabetes, the demand for HbA1c testing devices will rise rapidly especially in the Asia-Pacific, Latin America, MiddleEast and African regions. Moreover, advent of these devices for the diagnosis of diabetes will further bolster the demand for these devices in future. For instance, approval for the COBAS INTEGRA 800 Tina-quant HbA1cDx assay, in 2013and Abbott's ARCHITECT Clinical Chemistry Hemoglobin A1c (HbA1c) test approved in 2014 for the diagnosis of diabetes were the major steps in the hemoglobin A1c testing industry. With this diagnostic tools, physicians can combat the rising incidence of diabetes with timely and appropriate actions in identifying and managing diabetes. Based on the end-use, the global hemoglobin A1c testing devices market is categorized into two segments namely laboratory testing and point-of-care (POC) testing devices. Laboratory testing devices held the majority share of the market in 2012, while the global market for point-of-care testing devices is expected to grow at a faster paceduring the forecast period. Based on technologies, the hemoglobin A1c testing devices market is further categorized into five segments, namely, ion-exchange HPLC, immunoassay, boronate affinity chromatography, direct enzymatic assay and others. The boronate affinity chromatography market will be growing at a faster pace during the forecast period as this technology has no interference from hemoglobin variants and is also used in both laboratory as well as point-of-care testing. Healthcare practitioners are recommending the use of devices which offer least variant interference and this would elevate the demand for boronate affinity chromatography in HbA1c testing. The global hemoglobin A1c testing devices market is categorized into the following segments: Hemoglobin A1cTesting Devices Market, by End-use - Laboratory Testing Devices - Point-of-Care (POC)Testing Devices Hemoglobin A1cTesting Devices Market, by Technology - Ion-Exchange High Performance Liquid Chromatography (HPLC) - Immunoassay - Boronate Affinity Chromatography - Direct Enzymatic Assay - Others (Micro-Optical Detection Method and Capillary Electrophoresis) Key Topics Covered: - Introduction - Executive Summary - Global Hemoglobin A1c Testing Devices Market Overview - Global Hemoglobin A1c Testing Devices Market, by End-Use - Global Hemoglobin A1c Testing Devices Market, by Technology - Global Hemoglobin A1c Testing Devices Market, by Geography - Recommendations - Company Profiles - ARKRAY, Inc. - Abbott Laboratories - Alere, Inc. - Bio-Rad Laboratories, Inc. - Chek Diagnostics (Polymer Technology Systems, Inc.) - Danaher Corporation (Beckman Coulter) - EKF Diagnostics Holdings plc - F. Hoffmann-La Roche Ltd. - Menarini Group - Sebia - Siemens Healthcare - Tosoh Corporation - Trinity Biotech plc For more information visit http://www.researchandmarkets.com/research/bj...globin_a1c